Neuphoria Therapeutics Inc. · NASDAQ:NEUP
Neuphoria Therapeutics — Investor Presentation (July 2026)
35 slides from Neuphoria Therapeutics's investor presentation, Jul 24, 2026
Slide 1: Active Immunotherapy Ready For Prime Time
Corporate Presentation July 2026 Active Immunotherapy Ready For Prime Time
Slide 2: Disclaimer
2 Disclaimer This communication contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "believe", "expect", "plan", "anticipate", "estimate", "continue" and similar expressions (as
Slide 3: Investment Highlights
3 Investment Highlights Phase 3 ready, pipeline diversity, near term catalysts CPI=checkpoint inhibitors (Nivolumab and Ipilimumab); CRC=colorectal cancer; MSS=microsatellite stable cancer; NSCLC= non-small cell lung cancer; PDAC=Pancreatic ductal adenocarcinoma . 1. Subject to financing. * Checkmat
Slide 4: Robust, Diversified Pipeline with Partnership Opportunities
4 Robust, Diversified Pipeline with Partnership Opportunities Lead asset iSCIB1+ ready to enter phase 3 trial ADC=antibody-drug conjugate; CPI=checkpoint inhibitors; CRC=colorectal cancer; Ipi=Ipilimumab; MSS=microsatellite stable cancer; Nivo= Nivolumab; NSCLC= non-small cell lung cancer; PDAC=Panc
Slide 5: SCIB/iSCIB1+ Program in First Line Advanced Melanoma
5 SCIB/iSCIB1+ Program in First Line Advanced Melanoma
Slide 6: Despite Advent of Checkpoint Inhibitors, Significant Unmet Need in Melanoma
6 Despite Advent of Checkpoint Inhibitors, Significant Unmet Need in Melanoma Melanoma is the deadliest form of skin cancer CPI=checkpoint inhibitors. 1. Melanoma Research Alliance. https://www.curemelanoma.org/about-melanoma/melanoma-101. 2.WHO (2022) https://www.iarc.who.int/cancer-type/skin-cance
Slide 7: iSCIB1+'s Novel Dual Presentation MoA: Robust and Durable Anti-Tumor Response
7 iSCIB1+'s Novel Dual Presentation MoA: Robust and Durable Anti-Tumor Response Cross-presentation increases potency 100-fold In combination, checkpoint inhibitors unleash high-avidity iSCIB1⁺ T-cell–driven tumor killing 1. Processing of plasmid by muscle cells 2. Secretion of ImmunoBody 3. ImmunoBo
Slide 8: Stratis Allows for Patient-friendly Administration
8 Stratis® Allows for Patient-friendly Administration Minimal training required, similar workflow to needle and syringe Intramuscular delivery Needle-free (high velocity fluid jet) Hand-held with separate charging station Delivers injectables in ~1/10 of a second Broad global regulatory approval Dev
Slide 9: SCOPE Phase 2b Trial of SCIB/iSCIB1+ in 1L Advanced Melanoma
9 Cohort 3 (n=50, 40 Target HLA, 1 patient non-evaluable, 10 Non-Target) iSCIB1+ and nivolumab & ipilimumab Cohort 1 (n=43, 2 patients non evaluable) 1 SCIB1 and nivolumab & ipilimumab Target HLA (A2 haplotype only) Cohort 2 (n=10) stopped due to change in SOC SCIB1 and pembrolizumab Target HLA (A2
Slide 10: Trial Population Highly Aligned with 1L Melanoma Studies
1 0 Trial Population Highly Aligned with 1L Melanoma Studies Baseline patient characteristics Phase 2b SCOPE trial SCIB1 (n=43) iSCIB1+ (n=50) Gender Male 65% 42% Female 35% 58% Age <65 47% 66% ≥65 - <75 25% 30% ≥75 28% 4% Stage of Disease at Study Entry IIIB/IIIC/IV 1 IIIB / 42 IV 1 IIIC / 49 IV M0
Slide 11: Compelling Clinical Benefit Observed Across Multiple Endpoints
1 1 DCR=disease control rate; ORR=overall response rate IMCODE001: 2024 ASCO Annual Meeting, Relativity 047: N Engl J Med 2022;386:24-34, Checkmate 067: N Engl J Med 2017;377:1345-1356, IO Biotech: Annals of Oncology May 2026, RWE European Journal of Cancer, 2022; 176, 121-132 Data above are not fro
Slide 12: Strong Anti-tumor T Cell Responses Generated by iSCIB1+ Correlated with ORR
1 2 Strong Anti-tumor T Cell Responses Generated by iSCIB1+ Correlated with ORR Baseline Strongest T cell response 0 100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 Nomalised spot count per million cultured PBMCs <0.0001 Peptide recognised TRP2 180 gp100 174 gp100 471 TRP2 177 TRP2 60 g
Slide 13: SCIB1 & iSCIB1+ Well Tolerated with No Increase in CPI-Related Toxicities
1 3 SCIB1 & iSCIB1+ Well Tolerated with No Increase in CPI-Related Toxicities Treatment-Emergent Adverse Events amongst HLA matched, evaluable patients in C1, 3 & 4 (n=104) *Possibly related to mechanism of action. TEAEs, n(%) Related to: SCIB1/iSCIB1+ Related to CPI Dually Related (CPI + IMP) All g
Slide 14: iSCIB1+ Defined Regulatory Path Forward
1 4 iSCIB1+ Defined Regulatory Path Forward
Slide 15: Accelerated Approval Trial Design of iSCIB1+ in Advanced Melanoma
1 5 Accelerated Approval Trial Design of ISCIB1+ in Advanced Melanoma Phase 3 double blinded randomized registrational study cleared with FDA N = 550 at ~90 global sites Target Population: • Stage III & IV unresectable melanoma • HLA Haplotypes: A2, A3, A31, B35, B44, Bw4 • Exclude acral melanoma &
Slide 16: Defined Regulatory Path Forward for iSCIB1+
1 6 Defined Regulatory Path Forward for iSCIB1+ Building positive momentum through solid regulatory strategy Received IND clearance from FDA for the Phase 3 of iSCIB1+ in advanced melanoma Jan 2026 FDA Fast Track Designation Received CTA submitted to MHRA Apr 2026 Anticipated regulatory submissions
Slide 17: iSCIB1+ Program in Neoadjuvant/adjuvant melanoma
1 7 iSCIB1+ Program in Neoadjuvant/ adjuvant melanoma
Slide 18: Phase 1 SCIB1 Monotherapy Study in Resectable Melanoma
1 8 Partially or Fully Resected Stage III & IV Adjuvant Patients 1 PR & 3 SDs Observed at 8mg Dose 8mg dose (n=5) 0.1 -8mg dose (n=10) 4mg dose (n=15) 8mg dose (n=4) Lactose dehydrogenase (LDH) % Patient Demographics Phase 1 SCIB1 Monotherapy study in Resectable Melanoma In partially and fully resec
Slide 19: Compelling SCIB1 Monotherapy Activity in Neoadjuvant/Adjuvant Melanoma
1 9 Compelling SCIB1 Monotherapy Activity in Neoadjuvant/ Adjuvant Melanoma Data supports advancement to Phase 2 10 of 16 Patients remained disease-free at 60 months RFS: All patients alive at 39 months cut-off Patel et al, ONCOIMMUNOLOGY 2018 VOL. 0, NO. 0, e1433516 75% RFS at 39 months cut-off. Su
Slide 20: Proposed PoC Open-label, Randomized Study in Neoadjuvant/Adjuvant Setting
2 0 Proposed PoC Open-label, Randomized Study in Neoadjuvant/Adjuvant Setting Study builds on demonstration of monotherapy Melanoma Resectable Stage III – IV HLA Matched Randomization 1:1 Arm 1 iSCIB1+ Only Adjuvant for non-CPR (n = 150 (62% non-CPR)) EFS at 12, 18 & 24 months Neoadjuvant-adjuvant p
Slide 21: iSCIB1+ Commercial Opportunity
2 1 iSCIB1+ Commercial Opportunity
Slide 22: iSCIB1+ Demonstrates Deep and Durable Responses Across Multiple Endpoints
2 2 iSCIB1+ Demonstrates Deep and Durable Responses Across Multiple Endpoints in Broad Patient Population Scancell (Investigational) Immunocore (Investigational) Iovance (Investigational) BMS (Approved, now SoC) Therapy SCIB1/iSCIB1+ + ipi/ nivo iSCIB1+ accel dosing + ipi/ nivo Brenetafusp Lifileuce
Slide 23: Significant Commercial Opportunity for iSCIB1+
2 3 Significant Commercial Opportunity for iSCIB1+ Global peak sales potential up to $9bn in both advanced and earlier settings Bloomberg Melanoma Market Analysis 2026 | Peak sales based on predicted valuation of iSCIB1+ treatment and global addressable patient population Global peak sales potential
Slide 24: Strong Execution
2 4 Strong Execution
Slide 25: Experienced leadership executing with pace and precision
2 5 Experienced leadership executing with pace and precision Focus and execution drive value Phil L'Huillier Chief Executive Officer Professor Lindy Durrant Chief Scientific Officer & Founder Nermeen Varawalla Chief Medical Officer David Schilansky interim Chief Financial Officer Mandeep Sehmi Head
Slide 26: Key Milestones and Development Plans
2 6 Key Milestones and Development Plans NHS CVLP Partnership ✓ iSCIB1+ IND clearance ✓ iSCIB1+ Ph3 Trial initiation iSCIB1+ Neoadjuvant / adjuvant trial start iSCIB1+ Neoadjuvant / adjuvant trial interim readout iSCIB1+ Neoadjuvant / adjuvant trial readout iSCIB1+ Ph3 primary readout iSCIB1+ Regula
Slide 27: iSCIB1+ Has the Potential to Transform The Treatment of Advanced Melanoma
2 7 iSCIB1+ Has the Potential to Transform The Treatment of Advanced Melanoma • Phase 3 initiation in the U.S. anticipated in H2 2026 • CTA submitted to MHRA (UK), with imminent submissions to EMA, Canada and Australia regulatory agencies Multibillion dollars market opportunity: • iSCIB1+ initial pe
Slide 28: Additional Pipeline
Additional Pipeline 28 / SCANCELL
Slide 29: Moditope Off-the-shelf Peptide Vaccine
2 9 Moditope® Off-the-shelf Peptide Vaccine Targeting stress-induced post translational modifications Citrullination occurs due to autophagy induced in stressed cells, including cancer cells Citrullination protects from proteolytic cleavage and creates neo-epitopes Inflammation induces MHC class II
Slide 30: Modi-1 Pipeline & Clinical Development
3 0 Modi-1 Pipeline & Clinical Development Multi-cohort basket study conducted at 16 UK clinical sites enrolling over 120 patients Safety and dose selection confirmed in over 50 patients Ongoing cohorts evaluating Modi-1 in combination with SOC checkpoint inhibitors Modi-1 shows strong early efficac
Slide 31: Glymab Therapeutics: Targeting the Glycoproteome
3 1 TARGETING THE GLYCOPROTEOME Sialylation, Sulfation, Fucosylation Glycopeptides COMPREHENSIVE ANALYSIS Extensive characterisation using high density glycan arrays, IHC; SPR binding kinetics, target internalisation screens, ADCC NOVEL INTRACTABLE TARGETS: SLAN Protein + glycan combinations HIGHER
Slide 32: Thank You
YW SCANCELL Thank You
Slide 33: Appendices
Appendices 33 / SCANCELL
Slide 34: Experienced Board with Expertise In Biotechnology
3 4 Experienced Board with Expertise In Biotechnology Dr Jean-Michel Cosséry Chairman Susan Clement Davies Director Dr Ursula Ney Director Dr Florian Reinaud Director Martin Diggle Director Phil L'Huillier Director and Chief Executive Officer Prof Lindy Durrant Director and Chief Scientific Officer
Slide 35: Leveraging a Strong Advisory Board
3 5 Leveraging a Strong Advisory Board Purposefully mixing KOLs and Industry leaders Pippa Corrie Consultant Medical Oncologist, Cambridge Cancer Centre, Addenbrooke's Hospital, Cambridge Dirk Shadendorf Professor & Director of Department of Dermatology, University Hospital, Essen, Germany Alexander
Neuphoria Therapeutics — Investor Presentation (July 2026) on 6ix